|Articles|November 1, 2017
- Pharmaceutical Executive-11-01-2017
- Volume 37
- Issue 11
Pharmaceutical Executive, November 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive November 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 8 years ago
Pharm Exec's 2018 Pipeline Reportabout 8 years ago
Taiwan’s Biotech Boomabout 8 years ago
The Fine Line of Pharma & Patient Group Collaborationabout 8 years ago
FDA Explores Flexible Drug Marketing Policiesabout 8 years ago
No Overnight Successesabout 8 years ago
Aligning Early Advice with Long-Term Planningabout 8 years ago
Navigating the Untapped NASH Marketabout 8 years ago
Interpreting UK’s Post-Brexit Life Sciences Strategyabout 8 years ago
When HIPAA Doesn’t Applyabout 8 years ago
Country Report: AustriaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
2
JP Morgan 2026: Biogen’s New Company Emerges
3
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
4
JP Morgan 2026: Moderna Planning Seasonal Respiratory Vaccine Franchise
5